MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Shi JF, Chen JF, Canfell K, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Serv Res. 2012;12:123. doi:10.1186/1472-6963-12-12322624619
   PubMed Web of Science ®Google Scholar
• Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. Cancer Cell. 2004;5:533–538. doi:10.1016/j.ccr.2004.05.02915193256
   PubMed Web of Science ®Google Scholar
• Lukka H, Johnston M. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a meta-analysis. Clin Oncol. 2004;16:160–161. doi:10.1016/j.clon.2004.01.002
   Google Scholar
• Martín-Martínez A, Molano F, Lloret M, Falcón-Vizcaino O, García-Hernández JA. Concurrent chemotherapy and radiotherapy for cervical cancer. Eur J Gynaecol Oncol. 2003;24:160–162.12701969
   PubMed Web of Science ®Google Scholar
• Thomas GM. Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198–1200. doi:10.1056/NEJM19990415340150910202172
   PubMed Web of Science ®Google Scholar
• Chang RK, Li X, Mu N, et al. MicroRNA expression profiles in non‑epithelial ovarian tumors. Int J Oncol. 2018;52:55–66. doi:10.3892/ijo.2017.420029138809
   PubMed Web of Science ®Google Scholar
• Jiang YW, Chen LA. microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (Review). Mol Med Report. 2012;5:890–894. doi:10.3892/mmr.2012.776
   PubMed Web of Science ®Google Scholar
• Kim J, Yao F, Xiao Z, Sun Y, Ma L. MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev. 2018;37:5–15. doi:10.1007/s10555-017-9712-y29234933
   PubMed Web of Science ®Google Scholar
• Nair VS, Maeda LS, Ioannidis JPA. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst. 2012;104:528–540. doi:10.1093/jnci/djs02722395642
   PubMed Web of Science ®Google Scholar
• Bhome R, Del Vecchio F, Lee GH, et al. Exosomal microRNAs (exomiRs): small molecules with a big role in cancer. Cancer Lett. 2018;420:228–235. doi:10.1016/j.canlet.2018.02.00229425686
   PubMed Web of Science ®Google Scholar
• Glud M, Rossing M, Hother C, et al. Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 2010;20:479–484. doi:10.1097/CMR.0b013e32833e32a120827223
   PubMed Web of Science ®Google Scholar
• Shi M, Du L, Liu D, et al. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol. 2012;228:148–157. doi:10.1002/path.399722287315
   PubMed Web of Science ®Google Scholar
• Yang H, Xiaoli W, Kaihua W, et al. MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am J Cancer Res. 2016;6:2690–2699.27904781
   PubMed Web of Science ®Google Scholar
• Kikkawa N, Hanazawa T, Fujimura L, et al. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer. 2010;103:877–884. doi:10.1038/sj.bjc.660581120700123
   PubMed Web of Science ®Google Scholar
• Nohata N, Hanazawa T, Kikkawa N, et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br J Cancer. 2011;105:833–841. doi:10.1038/bjc.2011.31121847129
   PubMed Web of Science ®Google Scholar
• Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127:2804–2814. doi:10.1002/ijc.2528421351259
   PubMed Web of Science ®Google Scholar
• Moriya Y, Nohata N, Kinoshita T, et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet. 2012;57:38–45. doi:10.1038/jhg.2011.12622089643
   PubMed Web of Science ®Google Scholar
• Hidaka H, Seki N, Yoshino H, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3:44–57. doi:10.18632/oncotarget.41722294552
   PubMedGoogle Scholar
• Yoshino H, Chiyomaru T, Enokida H, et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011;104:808–818. doi:10.1038/bjc.2011.2321304530
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Hanazawa T, Nohata N, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget. 2012;3:1386–1400. doi:10.18632/oncotarget.70923159910
   PubMed Web of Science ®Google Scholar
• Alajez NM, Lenarduzzi M, Ito E, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011;71:2381–2391. doi:10.1158/0008-5472.CAN-10-275421385904
   PubMed Web of Science ®Google Scholar
• Uesugi A, Kozaki K, Tsuruta T, et al. The tumor suppressive microRNA miR-218 targets the mTOR component rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765. doi:10.1158/0008-5472.CAN-11-036821795477
   PubMed Web of Science ®Google Scholar
• Tie J, Pan Y, Zhao L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the ROBO1 receptor. PLoS Genet. 2010;6:e1000879. doi:10.1371/journal.pgen.100087920300657
   PubMed Web of Science ®Google Scholar
• Tatarano S, Chiyomaru T, Enokida H, et al. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 2011;39:13–21. doi:10.3892/ijo.2011.101221519788
   PubMed Web of Science ®Google Scholar
• Jingjing L, Wangyue W, Qiaoqiao X, Jietong Y. MiR-218 increases sensitivity to cisplatin in esophageal cancer cells via targeting survivin expression. Open Med. 2016;11:31–35. doi:10.1515/med-2016-0007
   Web of Science ®Google Scholar
• Li PL, Zhang X, Wang LL, et al. MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis. 2015;36:1484–1493. doi:10.1093/carcin/bgv14526442524
   PubMed Web of Science ®Google Scholar
• Hu Y, Xu K, Yagüe E. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat. 2015;151:269–280. doi:10.1007/s10549-015-3372-925900794
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kong Y, Yang W, et al. MicroRNA‑218 enhances gastric cancer cell cisplatin sensitivity by targeting surviving. Exp Ther Med. 2018;16:4796–4802. doi:10.3892/etm.2018.680230542435
   PubMed Web of Science ®Google Scholar
• Banno K, Iida M, Yanokura M, et al. MicroRNA in cervical cancer: oncomiRs and tumor suppressor miRs in diagnosis and treatment. Sci World J. 2014;2014:178075. doi:10.1155/2014/178075
   Google Scholar
• Nishikawa R, Goto Y, Sakamoto S, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Cancer Sci. 2014;105:802–811. doi:10.1111/cas.1244124815849
   PubMed Web of Science ®Google Scholar
• Brewer CA, Blessing JA, Nagourney RA, Mcmeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase ii study of the gynecologic oncology group. Gynecol Oncol. 2006;100:385–388. doi:10.1016/j.ygyno.2005.09.00916271750
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu M, Tang HK, et al. The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue squamous cell carcinoma. J Oral Pathol Med. 2012;41:141–148. doi:10.1111/j.1600-0714.2011.01066.x21793937
   PubMed Web of Science ®Google Scholar
• Olszewski U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem. 2010;10:293–301.20187870
   PubMed Web of Science ®Google Scholar
• Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov. 2006;1:1–22.18221023
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.8252621
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866. doi:10.1038/nrc199717060945
   PubMed Web of Science ®Google Scholar
• Fanini F, Vannini I, Amadori D, Fabbri M. Clinical implications of micrornas in lung cancer. Semin Oncol. 2011;38:776–780. doi:10.1053/j.seminoncol.2011.08.00422082763
   PubMed Web of Science ®Google Scholar
• Donzelli S, Mori F, Biagioni F, et al. MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther. 2014;2:16. doi:10.1186/2052-8426-2-1626056584
   PubMedGoogle Scholar
• Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 2013;16:47–59. doi:10.1016/j.drup.2013.05.00123757365
   PubMed Web of Science ®Google Scholar
• Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010;46:317–322. doi:10.1016/j.oraloncology.2010.02.00220219416
   PubMed Web of Science ®Google Scholar
• Ren W, Wang X, Gao L, et al. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4. Mol Cell Biochem. 2014;390:253–262. doi:10.1007/s11010-014-1976-824609942
   PubMed Web of Science ®Google Scholar
• Li J, Huang H, Sun L, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009;15:3998–4008. doi:10.1158/1078-0432.CCR-08-305319509158
   PubMed Web of Science ®Google Scholar
• Sun L, Yao Y, Liu B, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012;31:432–445. doi:10.1038/onc.2011.26321725369
   PubMed Web of Science ®Google Scholar
• Venkataraman S, Birks DK, Balakrishnan I, et al. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem. 2013;288:1918–1928. doi:10.1074/jbc.M112.39676223212916
   PubMed Web of Science ®Google Scholar
• Tu Y, Gao X, Li G, et al. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013;73:6046–6055. doi:10.1158/0008-5472.CAN-13-035823950210
   PubMed Web of Science ®Google Scholar
• Mathew LK, Skuli N, Mucaj V, et al. miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci USA. 2014;111:291–296. doi:10.1073/pnas.131434111124368849
   PubMed Web of Science ®Google Scholar
• Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 2010;70:10392–10401. doi:10.1158/0008-5472.CAN-10-234121159652
   PubMed Web of Science ®Google Scholar
• Kogo R, How C, Chaudary N, et al. The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 2015;6:1090–1100. doi:10.18632/oncotarget.283625473903
   PubMedGoogle Scholar
• Wu DW, Chuang CY, Lin WL, Sung WW, Cheng YW, Lee H. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. Carcinogenesis. 2014;35:1823–1829. doi:10.1093/carcin/bgu10224894864
   PubMed Web of Science ®Google Scholar
• Xie J, Yu F, Li D, Zhu X, Zhang X, Lv Z. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol. 2016;37:1197–1204. doi:10.1007/s13277-015-3831-226282001
   PubMedGoogle Scholar
• Tian H, Hou L, Xiong YM, et al. miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep. 2015;33:981–989. doi:10.3892/or.2014.365725482044
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Petanidis S, Kioseoglou E, Domvri K, Anestakis D, Zarogoulidis K. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal. 2015;27:1576–1588. doi:10.1016/j.cellsig.2015.04.00925917317
   PubMed Web of Science ®Google Scholar
• Chen DQ, Pan BZ, Huang JY, et al. HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget. 2014;5:3333–3349. doi:10.18632/oncotarget.194824830600
   PubMedGoogle Scholar
• Waligórska-Stachura J, Jankowska A, Waśko R, et al. Survivin–prognostic tumor biomarker in human neoplasms-review. Ginekol Pol. 2012;83:537–540.22880480
   PubMed Web of Science ®Google Scholar
• Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. Embo J. 2003;22:2729–2740. doi:10.1093/emboj/cdg26312773388
   PubMed Web of Science ®Google Scholar
• Singh N, Krishnakumar S, Kanwar RK, Cheung CH, Kanwar JR. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today. 2015;20:578–587. doi:10.1016/j.drudis.2014.11.01325433305
   PubMed Web of Science ®Google Scholar